The research, which comes from several groups including Genentech, makers of the prevailing anti-HER2 treatment, has researchers questioning ... By the late ’90s, a drug called Herceptin that targeted ...

These patients should be given Herceptin drug for treatment. Health Secretary Patricia Hewitt has already ordered the National Institute for Health and Clinical Excellence (NICE), the drugs ...

The PD-1 checkpoint inhibitor cancer treatment is fast becoming the backbone ... biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised ...

They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®.

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Without it, I’m looking at a bleaker five to 10 years’ prognosis compared to the 84 per cent survival rate with Herceptin treatment, delivered via infusion alongside my chemo drugs.

The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...

In the small group of study patients at M.D. Anderson who received Herceptin, says Buzdar, none so far has developed any heart problems almost two years after treatment. Some doctors have ...

Hence she and her family had to start a fundraising campaign to pay for her treatment privately. She has now started a year-long course of Herceptin at the Christie Hospital in Manchester.